Abstract 7: Differential Effect of Baseline Cta Collateral Status on Clinical Outcomes in Patients Enrolled in the Ims-3 Trial
Bibliographic record
Abstract
Introduction: In the IMS 3 trial, we test the hypothesis that a differential effect of endovascular therapy on clinical outcome will be most apparent in patients with severely ischemic but salvageable brain tissue (moderate collaterals on baseline CTA). Methods: Data is from patients in the IMS 3 study. Of 656 patients in the study, 306 patients had baseline CTA and 204 patients had M1 MCA +/_ intracranial ICA occlusion where baseline collaterals could be measured. Collateral status was assessed by consensus using 3 different scores and categorized as good, intermediate and poor. Details of the IMS 3 study protocol are described in the primary paper. Results: Of 204 patients, 138 received endovascular therapy (85.7% recanalized, 44.2% achieved 90-day mRS 0-2) and 66 received IV tPA only (57.1% recanalized, 36.4% achieved 90-day mRS 0-2). Proportion of patients with 90-day mRS 0-2 in good, intermediate and poor collateral categories between endovascular therapy and IV tPA across the 3 scores were: score 1(good: 56.5% vs. 41.7%, intermediate: 45.2% vs. 22.2%, poor: 18.4% vs. 23.5%); score 2 (good: 57.4% vs. 42.3%, intermediate: 40% vs. 23.1%, poor: 5.3% vs. 14.3%); score 3 (good: 51.6% vs. 42.3%, intermediate: 43.3% vs. 23.5%, poor: 20.6% vs. 18.8%). Using the van-Elteren test, a significant shift in 90-day mRS distribution in favor of endovascular therapy was noted only for subjects with intermediate collaterals. (p=0.01 for scores 1 and 2, Figure 1) Clinical outcome was poor with no differential effect of therapy in patients with poor collaterals. Conclusion: Patients with baseline intermediate collaterals have the highest likelihood of showing better clinical response to endovascular therapy. Future clinical trials testing IV tPA vs. endovascular therapy may have a higher likelihood of showing differential treatment effect if patients with baseline poor collaterals are excluded.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.006 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".